Atherotech Diagnostics Lab to Exhibit at American Diabetes Association 70th Scientific Sessions
6/24/2010 10:45:03 AM
BIRMINGHAM, Ala., June 23 /PRNewswire/ -- The patented VAP® Cholesterol Test helps physicians pinpoint the most effective cholesterol and heart disease risk-lowering treatments in Type 2 diabetes patients, providing valuable and potentially life-saving information to diabetics.
Atherotech Diagnostics Lab will exhibit its VAP Test and discuss advances in disease management at the premier conference for diabetes research and information. The American Diabetes Association (ADA) 70th Scientific Sessions takes place June 25-29, 2010, at the Orange County Convention Center in Orlando. Atherotech will exhibit the test and offer blood draws in booth #326.
Patients with Type 2 diabetes are at an increased risk of cardiovascular disease due to several factors, including lipoprotein abnormalities identified through cholesterol testing. Unlike other lipid profiles, the VAP Test directly measures all three lipoprotein parameters LDL, non-HDL and apoB considered necessary by the expert consensus guidelines issued by the ADA and American College of Cardiology.
"Not only does the VAP Test provide predictive factors for heart disease, it also allows physicians to manage therapy options for their diabetic patients at risk of heart attack and stroke," said Charles A. Reasner II, M.D., member of Atherotech's Medical Advisory Board and Professor of Medicine and Diabetes at the University of Texas Health Science Center in San Antonio. "VAP technology has been used in more than 100 clinical trials and will continue to play an important role in clinical practice and act as a valuable analytical research tool."
The VAP Test is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio and identifies markers of metabolic syndrome, often associated with early diabetes. It is the only advanced lipid profile that also routinely reports directly measured LDL-C, which is included in the 22 reported values of cholesterol all offered at no additional cost.
Atherotech provides physicians with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Representatives will be available at booth #326 to discuss new research, the VAP Test and cardiometabolic test options throughout the conference. Blood draws will be provided to qualified attendees during regular exhibit hours; fasting is not required.
For more information on the ADA Scientific Sessions, visit www.diabetes.org. For more information on the VAP Cholesterol Test and Atherotech's other cardiometabolic tests, visit www.atherotech.com or call 877.901.8510.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.
SOURCE Atherotech Diagnostics Lab